About this visual
An early readout on oral maintenance after injectable incretin treatment.
Sources & further reading
Original LinkedIn post and discussion ↗
Additional references appear in the infographic and the original LinkedIn discussion.

Originally posted Dec 2025 · By Joe Zucchi, PA-C, MPAS
1280 × 808 px · PDF includes the original image and a link to this page.
An early readout on oral maintenance after injectable incretin treatment.
Original LinkedIn post and discussion ↗
Additional references appear in the infographic and the original LinkedIn discussion.

A November 2026 overview of 12 investigational obesity therapies, spanning amylin-based treatments, GLP-1/GIP pathways, glucagon-containing combinations, and GLP-1 receptor agonists.

A six-slide overview of VK2735, covering injectable and oral Phase 2 results, exploratory maintenance dosing, dose-specific tolerability and Phase 3 programs.

A visual summary of sponsor-reported 80-week Phase 3 TRANSCEND-T2D-2 results comparing retatrutide with semaglutide 2 mg in adults with type 2 diabetes.
New Phase 3 data from Lilly’s ATTAIN-MAINTAIN trial highlight an important advance in long-term obesity care.
After achieving weight loss on injectable incretin therapies in SURMOUNT-5, patients who had reached a weight plateau were transitioned to once-daily oral orforglipron for maintenance. At 52 weeks, orforglipron demonstrated superior weight maintenance compared with placebo.
Key findings:
• From Wegovy to orforglipron: average change of +0.9 kg
• From Zepbound to orforglipron: average change of +5.0 kg
• Placebo groups experienced substantially greater weight regain
These results reinforce obesity as a chronic disease that often requires ongoing pharmacologic support. With oral orforglipron under FDA review and oral Wegovy expected soon, it is encouraging to see more long-term treatment options emerging. Now we need to continue making progress regarding cost reduction and coverage improvements to expand access.
My infographic below summarizes the trial design and key results.